Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GD2 monoclonal antibody BCD-245

A monoclonal antibody directed against the tumor-associated antigen (TAA) disialoganglioside (GD2; GD-2), with potential antineoplastic activity. Upon administration, anti-GD2 monoclonal antibody BCD-245 may induce cytotoxicity in GD2-expressing tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC). GD2 is overexpressed on the surface of neuroblastoma (NB) cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GD-2 monoclonal antibody BCD-245
Code name:BCD 245
BCD-245
BCD245
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search